Eighteen months after its entrance into the U.S. market, Genentech's Ocrevus (ocrelizumab) has become the monoclonal antibody of choice to treat ... read more
Ocrevus Climbing as First-line DMT of Choice Among Neurologists Surveyed in Spherix Report
Ocrevus Climbing as First-line DMT of Choice Among Neurologists Surveyed in Spherix Report